Peptides

BPC-157: what the human evidence actually shows, and what the FDA advisory vote did and did not change

By the US Health Digest editorial team · July 28, 2026

On Thursday, July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the list of bulk substances compounding pharmacies may use — and that vote did not make BPC-157 legal, approved, or proven. The recommendation is non-binding, and as TIME reported, any addition "will still have to go through a lengthy public rulemaking process." FDA's own scientists recommended against it, concluding in their briefing document that "a balancing of the criteria weighs against" listing it. That document is also the fullest public audit of the evidence, and it is thin: five human studies exist, only one of them a randomized trial in patients with a disease — a two-week rectal-enema trial in ulcerative colitis, published only as a conference abstract, in which 53 subjects were randomized and 46 completed. BPC-157 is not approved as a drug in any country, and we publish no dosing for it.

What BPC-157 is, and what it is sold for

BPC-157 is a synthetic 15-amino-acid peptide, described by FDA as "a pentadecapeptide fragment of the BPC protein originally isolated from human gastric juice," first reported in 1993. It has no US Adopted Name, no pharmacopeial monograph, and is in no approved drug. Marketing runs well ahead of that: FDA catalogued vendor and clinic claims it will "accelerate the healing of injuries and wounds, including gastric ulcers, tendons, ligaments and bones." FDA assessed one use, ulcerative colitis — the only one documented well enough to evaluate.

What the human evidence actually shows

FDA's search of the published medical literature in PubMed and Embase found five clinical studies that have ever given BPC-157 to humans. Its appendix lists all five; we reproduce it without doses.

Source: FDA briefing document, Appendix 1. About 116 people were enrolled across the five studies, and roughly 80 of them actually received BPC-157 on FDA's own tally of who was dosed. Three of the five studies come from one investigator.

The one randomized trial in patients

Ruenzi 2005 exists only as a conference abstract, and its primary endpoint — a "Disease Activity Index" — is never defined there. FDA reports a between-group difference of 1.6 points (95% CI −4.84, 1.62). That interval spans zero, which means the trial did not demonstrate a difference between BPC-157 and placebo. It does not mean the trial showed there is no difference: 46 people over two weeks is too small to establish either conclusion. FDA judged the data "inadequate to support the efficacy and safety" of the treatment.

Everything else is rodents

The preclinical literature is large — three decades, largely from one Croatian group. A 2025 systematic review in the HSS Journal included 36 studies, 35 preclinical and one clinical. A 2026 review in Pharmaceutics found BPC-157 has "no approved formulation, no validated dosing regimen, and no completed Phase II clinical trial." Flynn McGuire, a chief medical resident at University of Utah Health, put the translation gap to STAT: "We've cured cancer in mice plenty of times. Haven't done it in people yet."

FDA adds that dose-response is unestablished, that "the molecular targets … have not been identified," and that in humans there is "insufficient clinical safety information to characterize the safety profile." None of this shows BPC-157 is useless. It shows almost nothing is known.

The contrast that matters

Peptides are a chemical class, not a quality tier. GLP-1 drugs are peptides too, at the far end of the spectrum: STEP 1 randomized 1,961 adults and reported 14.9% mean weight loss at 68 weeks versus 2.4% on placebo — one phase-3 trial among many. When someone says "peptides work," ask which peptide, and see what a peptide is.

The legal status, precisely

What the 503A bulks list is

Under section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacist compounding for one patient may use a bulk substance only if it has a USP or NF monograph, is in an approved drug, or appears on a specific FDA list. BPC-157 meets none of the three, as FDA told a compounder in a 2019 warning letter. Getting onto that list is a rulemaking, not a vote: it was created by a 2019 final rule, and additions require notice-and-comment rulemaking.

Category 2, and 2023

Pending evaluation, FDA sorts nominated substances under an interim policy; Category 2 covers those it says may present "significant safety risks." FDA placed these peptides there in 2023; as TIME put it, the seven were "among more than a dozen that the FDA essentially banned compounding pharmacies from dispensing." BPC-157 no longer appears in Category 2 on FDA's page, updated April 22, 2026; it now sits among substances nominated but withdrawn. Wider claims of a wholesale peptide reclassification could not be confirmed from FDA or a named news outlet, so we do not report them.

The seven peptides, July 23–24, 2026

Agenda and evaluated uses from FDA. Tallies as reported by STAT, which describes BPC-157, KPV and TB-500 as carried in a single 8–6 vote; the day-one tallies and the abstentions are corroborated by Pharmaceutical Executive, and the BPC-157 tally by ABC News and TIME. Read the totals with care: they do not sum to a constant number of members — 15 for BPC-157, 14 for MOTs-C, 13 for Emideltide and Semax, 11 for Epitalon — so the number of members present, voting and abstaining varied across the two days. FDA has not published a per-vote roster, so we cannot reconcile the difference, and these figures should be read as what news outlets reported rather than as an official record.

An advisory vote is not a legal change

FDA's own description is that advisory committees "make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so." ABC News reported FDA scientists "highlighted a general lack of quality data supporting safety and effectiveness," and that members voting no feared listing would create "a false impression that it has been evaluated with the same rigorous standards as an FDA-approved drug." Committee member Dr. Elizabeth Rebello told TIME: "I'm concerned that we're responding to a market-induced demand rather than a decision based in solid science." Nina Zeldes of Public Citizen said its supposed benefits are "largely based on anecdotal evidence." Nothing about BPC-157's legal status changed on July 23. As with the compounded GLP-1 wind-down and the compounded-versus-branded question, compounded is not a synonym for approved.

"Research use only" is a marketing label, not a legal shield

Most retail BPC-157 carries a disclaimer that it is for research, not human consumption. In a March 2026 warning letter, FDA told a peptide seller: "Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use." Where the marketing describes health benefits, FDA treats the product as an unapproved new drug regardless. The label protects the storefront, not the buyer.

Purity, counterfeits and certificates of analysis

We could not find published independent purity testing of retail BPC-157, and we will not invent a figure: purity data on this supply chain is scarce. What is documented is narrower but telling. In both nomination packages FDA evaluated, the certificate of analysis did not match the substance nominated — each supplied a CoA for BPC-157 acetate while the identifying codes matched BPC-157 free base. If nominators filing to a federal docket sent mismatched paperwork, a certificate emailed by an unregulated vendor warrants no automatic trust.

Peptides also aggregate and degrade, and aggregates and impurities drive immunogenicity; given by injection or nasally, FDA concluded, BPC-157 "may pose a significant risk for immunogenicity." One of three reports in FDA's adverse-event database describes a woman who used a product labeled "research purposes only," developed diffuse hyperpigmentation and gingival darkening, and redeveloped identical reactions on rechallenge. FDA notes that the product contained two peptides — BPC-157 and TB-500 — so the reaction cannot be attributed to BPC-157 itself, and that FAERS reports in general cannot establish causation. Matthew Fedoruk, chief science officer of the US Anti-Doping Agency, told STAT: "You don't even know what you're buying inside that bottle. It could be a peptide. It could be a steroid. It could be something just like water."

Sport, and why we publish no dose

Athletes under anti-doping rules should treat BPC-157 as prohibited. FDA's briefing document states that "BPC-157 is listed on the World Anti-Doping Agency's prohibited list under the non-approved substances (S0) section," citing WADA's list as accessed December 4, 2025. WADA's site could not be retrieved for direct verification, so we attribute this to FDA.

We publish dosing for medicines with approved labels, because a label reflects the trials that set the dose. BPC-157 has no approved indication, no validated regimen, and — per FDA — no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal administration. Anything we printed would be guesswork dressed as guidance. The most rigorous work underway is a registered hamstring-strain trial, NCT07437547; an earlier phase 1 study, NCT02637284, posted no results.

Questions to ask a clinician who offers you BPC-157

• Is BPC-157 an approved drug for anything, in any country? (Per FDA, no.)
• How many randomized human trials support the use you propose — can you name them?
• FDA found no human studies of BPC-157 given orally, subcutaneously, nasally or transdermally. If you propose one of those, what are you relying on?
• Is the pharmacy a registered 503A or 503B facility, and may I see the certificate of analysis — including whether it covers the free base or the acetate?
• What would make you stop treatment, and which adverse effects should I report?
• What are the approved options for my condition, and why not try those first?

Readers can compare against our GLP-1 FAQ and our review of what the semaglutide trials reported. The difference is not opinion: one drug ran phase-3 trials; the other's published human record fits in a five-row table.